A Phase 1b, Open-Label, Dose-Escalation, Dose-Expansion, and Dose-Randomization Study of IO 108 as Monotherapy and in Combination With Either Pembrolizumab or Cemiplimab in Adult Patients With Advanced Solid Tumors
Latest Information Update: 11 Jun 2024
At a glance
- Drugs Cemiplimab (Primary) ; IO-108 (Primary) ; Pembrolizumab (Primary)
- Indications Cholangiocarcinoma; Colorectal cancer; Merkel cell carcinoma; Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Immune-Onc Therapeutics
- 31 May 2024 Status changed from active, no longer recruiting to completed.
- 13 Mar 2024 Planned End Date changed from 30 Dec 2024 to 26 Apr 2024.
- 13 Mar 2024 Planned primary completion date changed from 30 Dec 2023 to 29 Mar 2024.